Category: hypoactive sexual desire dysfunction HSDD
TGA accepts Lawley product for evaluation in postmenopausal women with HSDD.
Posted: December 5, 2019
TGA accepts Lawley product for evaluation in postmenopausal women with HSDD. Perth, Western Australia; Dec. 05, 2019 — Lawley Pharmaceuticals Pty Ltd today announced… Continue Reading →
Global Consensus Position Statement on the Use of Testosterone Therapy for Women
Posted: November 26, 2019
The Global Consensus Position Statement on the Use of Testosterone Therapy for Women was simultaneously published on the 2nd September 2019 in Maturitas, Journal… Continue Reading →